3R Pharma

Company Overview

Snapshot

Founded in February 2020 by Michael Rubinov, 3R Pharma operates with 1–10 employees. The company has raised $800K across two funding rounds from five investors. In February 2023, 3R Pharma received a follow-on investment from the Israeli Innovation Authority and CanNegev Incubator.

Business overview

3R Pharma is a Health Tech & Life Sciences company focused on developing high-end, complex cannabinoid-based pharmaceutical products. The company's core technology involves patent-pending cannabinoid-based medicines designed to address chronic ocular diseases. Serving the pharmaceutical market, 3R Pharma aims to provide novel treatment options for conditions currently insufficiently addressed.

Strategic signal

In February 2023, 3R Pharma announced a follow-on investment from the Israeli Innovation Authority and CanNegev Incubator. This indicates continued strategic validation and financial support for the company's research and development efforts in cannabinoid-based ophthalmic solutions, signaling ongoing progress in its product development pipeline.

Company Intelligence Q&A

What is the current operational status of 3R Pharma?

3R Pharma is currently non-active, having ceased operations in April 2026.

When was 3R Pharma founded and by whom?

3R Pharma was founded in February 2020 by Michael Rubinov.

What was a significant recent development for 3R Pharma?

In February 2023, 3R Pharma announced a follow-on investment from the Israeli Innovation Authority and CanNegev Incubator.

What was the company's total capital raised?

3R Pharma has raised a total of $800K across two funding rounds.

What was the earliest disclosed funding event for 3R Pharma?

In October 2021, 3R Pharma received a seed investment from the Israel Innovation Authority and OurCrowd.